Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6565999 | 0.93 | IDO1 (0.43) | GAAALDH1A1LMNAKDM4ECFTR | |
| SCHEMBL6567992 | 0.91 | SLC6A4 (0.39) | GAAALDH1A1LMNAKDM4ECFTR | |
| SCHEMBL6567822 | 0.89 | ABL1 (0.39) | GAAALDH1A1LMNAKDM4EKMT2A | |
| SCHEMBL6566099 | 0.87 | CFTR (0.43) | GAAALDH1A1LMNAKDM4ECFTR | |
| SCHEMBL6566564 | 0.83 | GAA (0.40) | GAAALDH1A1KDM4ECFTRHSD17B10 | |
| SCHEMBL6564533 | 0.82 | GAA (0.48) | GAAALDH1A1LMNAKDM4ECFTR | |
| SCHEMBL6567802 | 0.81 | MAPT (0.47) | GAAALDH1A1LMNAKDM4EKMT2A | |
| SCHEMBL6564586 | 0.81 | SLC6A4 (0.42) | GAAALDH1A1LMNAKDM4ECFTR | |
| SCHEMBL6564770 | 0.80 | GAA (0.39) | GAAALDH1A1KDM4ECFTRHSD17B10 | |
| SCHEMBL6712343 | 0.80 | IDO1 (0.47) | GAAALDH1A1LMNAKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | GAA 3305/4885ALDH1A1 907/4885LMNA 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.